The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 52,303 | - |
| Payroll and related costs | 52,589 | - |
| Lab supplies and outside services | 10,595 | - |
| Facility costs | 7,329 | - |
| Professional services | 8,341 | - |
| Repairs and maintenance | 6,381 | - |
| Change in fair value of the tempus warrants | 0 | - |
| Depreciation and amortization | 7,523 | - |
| Other segment items | 22,588 | - |
| Interest income | 5,585 | - |
| Net loss | -21,652 | -35,806 |
| Stock-based compensation expense | 2,082 | 5,049 |
| Depreciation and amortization | 2,466 | 5,118 |
| Noncash operating lease cost | 405 | 799 |
| Amortization of discount on short-term investments | 942 | 2,204 |
| Other | -34 | 263 |
| Accounts receivable | 4,424 | 1,812 |
| Inventory and other deferred costs | -780 | -504 |
| Prepaid expenses and other assets | 142 | 1,133 |
| Accounts payable | -990 | 3,721 |
| Accrued and other current liabilities | 1,818 | -1,294 |
| Contract liabilities | -169 | -1,475 |
| Operating lease liabilities | -1,020 | -2,000 |
| Other long-term liabilities | -50 | -100 |
| Net cash used in operating activities | -21,804 | -30,896 |
| Purchases of available-for-sale debt securities | 48,150 | 108,297 |
| Proceeds from maturities of available-for-sale debt securities | 68,500 | 84,185 |
| Purchases of property and equipment | 1,626 | 2,801 |
| Net cash used in investing activities | 18,724 | -26,913 |
| Proceeds from sales of common stock under atm facility, net of commissions | 0 | 17,782 |
| Payment of costs related to tempus and merck investment agreements | 0 | 106 |
| Proceeds from loans | 0 | 2,587 |
| Repayments of loans | 411 | 1,307 |
| Proceeds from issuance of common stock under equity incentive plans | 94 | 804 |
| Net cash provided by financing activities | -317 | 19,760 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -4 | 8 |
| Net change in cash, cash equivalents and restricted cash | -3,401 | -38,041 |
| Cash and cash equivalents at beginning of period | 93,205 | - |
| Cash and cash equivalents at end of period | 51,763 | - |
Personalis, Inc. (PSNL)
Personalis, Inc. (PSNL)